Why climate-focussed equity investors might want to take a look at Volution. Synopsis Track record in climate action. Volution has a strong track record in climate action. It boasts impressive green credentials, including the London Stock Exchange Green Economy Mark, the FT Europe Climate Leaders award, and full SBTi approval for its near- and long-term emission reduction targets. Products lead to lower emissions.  The group develops and manufactures a wide-ranging and growi

Basilea announced the receipt of a $30 million milestone payment this morning, as its leading antifungal, Cresemba, exceeded the predetermined sales threshold in Europe. The receipt of this significant sales milestone from European licensee Pfizer is a testament to the continued strong growth of Cresemba, despite its maturity, and thanks to its profile, which combines a broad spectrum with a favourable side-effect profile. Efforts at Basilea to prepare for the loss of exclusi

Our research note today highlights the opportunities available from Basilea's existing portfolio and pipeline. Basilea addresses the...

Basilea announced this morning that it has received a further $25 million in non-dilutive funding from BARDA to support the development...

The H1 period at Basilea was notable for another strong performance from the anti-fungal Cresemba (isavuconazole). Underlying growth was...

Basilea announced this morning that it has acquired the global rights to the Phase 3-ready beta-lactam/beta-lactamase inhibitor,...